24 November 2025 in Journal of Clinical Ultrasound
9 November 2025 in Clinical Case Reports
Angiomyolipoma (AML) is a rare benign mesenchymal tumor, constituting less than 10% of renal masses, and occurs sporadically or in association with tuberous sclerosis complex (TSC). AML is generally categorized into classic AML and epithelioid angiomyolipoma (EAML), with the latter comprising approximately 4.6% of AML cases. EAML is characterized by a predominance of epithelioid cells, minimal adipose tissue, and distinct histological features such as necrosis and potential malignancy, which can lead to misdiagnosis as renal cell carcinoma (RCC). This report presents a case of renal EAML in a 27‐year‐old Iranian woman with mild left flank pain and hematuria, with imaging studies revealing an echogenic mass in the left kidney suggestive of AML. Contrast‐enhanced computed tomography and magnetic resonance imaging confirmed a heterogeneous mass with fat content. Histopathological examination post‐partial nephrectomy revealed a carcinoma‐like lesion with a proliferation of epithelioid cells, necrosis, and scattered giant cells, consistent with EAML. Notably, the tumor exhibited low mitotic activity and lacked atypical mitoses, confirming its benign nature. Despite the rarity of EAML and the lack of distinct clinical or radiological features, this case underscores the importance of pathological findings for accurate diagnosis. The management of EAML remains challenging due to its aggressive potential; however, surgical intervention is often the gold standard treatment. This case contributes to the limited literature on EAML, emphasizing the need for further research to establish definitive diagnostic criteria and treatment guidelines to address its clinical uncertainties.
31 May 2026 in Hemodialysis International
30 June 2026 in BioImpacts
DNDiana Jafari Nakhjavani
Glomerulonephritis (GN) is a heterogeneous group of kidney diseases characterized by inflammation and damage to the glomeruli. Current treatments for GN remain suboptimal, creating a pressing need for innovative therapeutic strategies. Short interfering RNAs (siRNAs) represent a promising advance in the therapeutic landscape for GN, offering targeted gene silencing that could fundamentally transform the management of this significant cause of kidney disease. siRNA therapies work by selectively silencing specific genes involved in the pathogenesis of GNs, including interferon pathways, B cell activation, TGF-β, MAPK1, HMGB1, BLYSS, and SIRT1. Preclinical evidence demonstrates improved kidney function and reduced glomerular damage in experimental models. While challenges remain in translating these findings to clinical applications, ongoing research suggests that siRNA-based therapies have the potential to transform the treatment of GN, offering new hope for patients with this challenging kidney disease. This review highlights the impact of siRNA-based therapies in GN, exploring their mechanisms, delivery systems, challenges, and preclinical and clinical evidence.
10 June 2025 in Journal of Renal Injury Prevention
Introduction: Studies have shown that patients with chronic kidney failure and patients under dialysis have a significantly augmented risk of developing cognitive damage compared to the general population. Objectives: The purpose of this study was to explore cognitive function in people with end-stage kidney disease (ESKD) under hemodialysis or peritoneal dialysis who were referred to the dialysis center of Imam Reza Hospital in 2024. Materials and Methods: This cross-sectional study included 200 patients (100 patients under hemodialysis and 100 patients under peritoneal dialysis). Through a standardized MMSE (mini-mental state examination) questionnaire, the cognitive function of the patients was examined and compared between the two groups. Results: In this study, all variables of cognitive function including awareness of time (P<0.001), awareness of place (P<0.001), recall (P<0.001), attention and calculation (P<0.001), drawing (P=0.003), and MMSE total score (P<0.001) were significantly higher in patients under peritoneal dialysis in compared to patients under hemodialysis. Conclusion: Cognitive function appears to be significantly better in patients with ESKD under peritoneal dialysis than in those under hemodialysis. Given the high prevalence of cognitive impairment and its association with adverse outcomes, routine cognitive screening and individualized management strategies should be considered, regardless of dialysis modality.
3 December 2025 in Clinical Case Reports
BGBehrooz Shokouhi Gogani
Xanthogranulomatous endometritis (XGE), typically a postmenopausal condition, has been diagnosed for the first time in a pregnant woman. This case also demonstrates the first reported association of XGE with high‐grade serous ovarian carcinoma, underscoring the need for malignancy screening in XGE patients, regardless of pregnancy status. This highlights the importance of prompt histopathological sampling to prevent misdiagnosis.